Jing Huang is a Dermatology physician affiliated with University at Buffalo. OpenAlex indexes 97 publications with 2,488 citations (h-index 20); ClinicalTrials.gov lists 25 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3600 Spruce St
Philadelphia, PA 191044211
Telephone
215-662-2737Registry record last updated 21 Jul 2022.
Clinical trials
- A Clinical Trial of SIBP-A18 Injection in the Treatment of Advanced Malignant Solid Tumor Patients
Sponsor: Shanghai Institute Of Biological Products
- A Clinical Trial of SIBP-A17 Injection in the Treatment of Advanced Solid Tumor Patients.
Sponsor: Shanghai Institute Of Biological Products
- A Phase I Clinical Trial to Evaluate LIT-00814 Tablets in Patients With Advanced Solid Tumor
Sponsor: LittDD Medicines Ltd
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
32%Azole Antifungal14.5%Ketoconazole100%Part D≥50 patientsNitroimidazole Antimicrobial5%Metronidazole100%Part D<11 patients+ 3 more classes in this area
Sensory organs
19.5%Corticosteroid19.5%Hydrocortisone57%Clobetasol Propionate43%Part D≥61 patientsCancer & immunology
15.8%Nucleoside Metabolic Inhibitor9.5%Fluorouracil100%Part D≥48 patientsRetinoid2.3%Tretinoin100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2019–2026 per NIH RePORTER. The latest:
- Advancing Craniosynostosis Treatment (ACT)Rare Diseases Consortium
Children'S Hosp of Philadelphia
FY2026$1,562,624U54DE035976 - Advancing Craniosynostosis Treatment (ACT)Rare Diseases Consortium
Children'S Hosp of Philadelphia
FY2025$1,530,000U54DE035976 - Characterizing dynamics of pandemic and preparing for speedy and accurate response
Children'S Hosp of Philadelphia
FY2024$1U01CK000674
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Anne Curtis, MD
University at Buffalo
Paresh Dandona, MD
University at Buffalo
Gil Wolfe, MD
University at Buffalo
Uriel Halbreich, MD
University at Buffalo
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”